Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947954703> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W2947954703 endingPage "TPS5093" @default.
- W2947954703 startingPage "TPS5093" @default.
- W2947954703 abstract "TPS5093 Background: Early and accurate detection of recurrent or metastatic prostate cancer remains an unmet diagnostic need for patient management. While agents for positron emission tomography (PET), such as 11 C-choline and 18 F-fluciclovine, have emerged as options for imaging recurrent prostate cancer, these agents are not specific for the disease. 18 F-DCFPyL is a novel, low-molecular weight, PET radiopharmaceutical that binds selectively to prostate-specific membrane antigen with high affinity. In prior studies, 18 F-DCFPyL PET/CT has shown reliable diagnostic performance in detecting metastatic or recurrent prostate cancer (Rowe Mol Imaging Biol 2016 18:411-19; Gorin J Urol 2018 1999:126-32). Methods: CONDOR is a phase 3, multicenter, open-label study designed to assess the diagnostic performance and clinical impact of 18 F-DCFPyL PET/CT in men with suspected recurrent or metastatic prostate cancer. Approximately 200 patients are planned to be enrolled across 15 centers in the United States and Canada. Eligible patients ≥18 years of age must have histologically confirmed prostate adenocarcinoma, have rising PSA after definitive therapy, and negative or equivocal conventional imaging. A single 9 mCi (333 MBq) dose of 18 F-DCFPyL is administered, followed by whole body PET/CT scan 1 hour later. The primary objective is to assess the correct localization rate (percentage of patients with a one-to-one correspondence between localization of at least one lesion identified on 18 F-DCFPyL PET/CT and the composite truth standard, defined as either evaluable histopathology, informative correlative imaging, or PSA response after radiation therapy). Additional study objectives include safety and tolerability of 18 F-DCFPyL, impact on intended treatment plans, detection rates and PPV of 18 F-DCFPyL by region, and detection rates by baseline PSA. 18 F-DCFPyL PET/CT results are centrally reviewed by independent readers blinded to all clinical and other imaging information. As of February 9, 2019, a total of 36 patients have been dosed in the study. Clinical trial information: NCT03739684." @default.
- W2947954703 created "2019-06-07" @default.
- W2947954703 creator A5006645866 @default.
- W2947954703 creator A5013108068 @default.
- W2947954703 creator A5017288060 @default.
- W2947954703 creator A5033878032 @default.
- W2947954703 creator A5038489605 @default.
- W2947954703 creator A5040347024 @default.
- W2947954703 creator A5047560321 @default.
- W2947954703 creator A5049988109 @default.
- W2947954703 creator A5056969058 @default.
- W2947954703 creator A5065938090 @default.
- W2947954703 creator A5067187971 @default.
- W2947954703 creator A5071268553 @default.
- W2947954703 creator A5087839705 @default.
- W2947954703 date "2019-05-20" @default.
- W2947954703 modified "2023-09-27" @default.
- W2947954703 title "A phase III, multicenter study to assess the diagnostic performance and clinical impact of <sup>18</sup>F-DCFPyL PET/CT in men with suspected recurrence of prostate cancer (CONDOR)." @default.
- W2947954703 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.tps5093" @default.
- W2947954703 hasPublicationYear "2019" @default.
- W2947954703 type Work @default.
- W2947954703 sameAs 2947954703 @default.
- W2947954703 citedByCount "4" @default.
- W2947954703 countsByYear W29479547032020 @default.
- W2947954703 countsByYear W29479547032021 @default.
- W2947954703 countsByYear W29479547032022 @default.
- W2947954703 crossrefType "journal-article" @default.
- W2947954703 hasAuthorship W2947954703A5006645866 @default.
- W2947954703 hasAuthorship W2947954703A5013108068 @default.
- W2947954703 hasAuthorship W2947954703A5017288060 @default.
- W2947954703 hasAuthorship W2947954703A5033878032 @default.
- W2947954703 hasAuthorship W2947954703A5038489605 @default.
- W2947954703 hasAuthorship W2947954703A5040347024 @default.
- W2947954703 hasAuthorship W2947954703A5047560321 @default.
- W2947954703 hasAuthorship W2947954703A5049988109 @default.
- W2947954703 hasAuthorship W2947954703A5056969058 @default.
- W2947954703 hasAuthorship W2947954703A5065938090 @default.
- W2947954703 hasAuthorship W2947954703A5067187971 @default.
- W2947954703 hasAuthorship W2947954703A5071268553 @default.
- W2947954703 hasAuthorship W2947954703A5087839705 @default.
- W2947954703 hasConcept C121608353 @default.
- W2947954703 hasConcept C126322002 @default.
- W2947954703 hasConcept C126838900 @default.
- W2947954703 hasConcept C20417620 @default.
- W2947954703 hasConcept C2775842073 @default.
- W2947954703 hasConcept C2776235491 @default.
- W2947954703 hasConcept C2779466945 @default.
- W2947954703 hasConcept C2780192828 @default.
- W2947954703 hasConcept C2909113890 @default.
- W2947954703 hasConcept C2989005 @default.
- W2947954703 hasConcept C71924100 @default.
- W2947954703 hasConceptScore W2947954703C121608353 @default.
- W2947954703 hasConceptScore W2947954703C126322002 @default.
- W2947954703 hasConceptScore W2947954703C126838900 @default.
- W2947954703 hasConceptScore W2947954703C20417620 @default.
- W2947954703 hasConceptScore W2947954703C2775842073 @default.
- W2947954703 hasConceptScore W2947954703C2776235491 @default.
- W2947954703 hasConceptScore W2947954703C2779466945 @default.
- W2947954703 hasConceptScore W2947954703C2780192828 @default.
- W2947954703 hasConceptScore W2947954703C2909113890 @default.
- W2947954703 hasConceptScore W2947954703C2989005 @default.
- W2947954703 hasConceptScore W2947954703C71924100 @default.
- W2947954703 hasIssue "15_suppl" @default.
- W2947954703 hasLocation W29479547031 @default.
- W2947954703 hasOpenAccess W2947954703 @default.
- W2947954703 hasPrimaryLocation W29479547031 @default.
- W2947954703 hasRelatedWork W2321373517 @default.
- W2947954703 hasRelatedWork W2894564812 @default.
- W2947954703 hasRelatedWork W2983834681 @default.
- W2947954703 hasRelatedWork W2986849265 @default.
- W2947954703 hasRelatedWork W3025248830 @default.
- W2947954703 hasRelatedWork W3030930135 @default.
- W2947954703 hasRelatedWork W3094608289 @default.
- W2947954703 hasRelatedWork W4220943898 @default.
- W2947954703 hasRelatedWork W4281715506 @default.
- W2947954703 hasRelatedWork W4293020281 @default.
- W2947954703 hasVolume "37" @default.
- W2947954703 isParatext "false" @default.
- W2947954703 isRetracted "false" @default.
- W2947954703 magId "2947954703" @default.
- W2947954703 workType "article" @default.